View metadata, citation and similar papers at core.ac.uk

brought to you by CORE

provided by Edinburgh Research Explorer

THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

sAPP and sAPP increase structural complexity and E/I input ratio in primary hippocampal neurons and alter Cahomeostasis and CREB1-signaling

Citation for published version:
Hesse, R, von Einem, B, Wagner, F, Bott, P, Schwanzar, D, Jackson, RJ, Föhr, KJ, Lausser, L, Kroker, KS, Proepper, C, Walther, P, Kestler, HA, Spires-Jones, TL, Boeckers, T, Rosenbrock, H & von Arnim, CAF 2018, 'sAPP and sAPP increase structural complexity and E/I input ratio in primary hippocampal neurons and alter Cahomeostasis and CREB1-signaling' Experimental neurology, vol. 304, pp. 1-13. DOI: 10.1016/j.expneurol.2018.02.010

Digital Object Identifier (DOI):
10.1016/j.expneurol.2018.02.010

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Experimental neurology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 05. Apr. 2019

sAPPβ and sAPPα increase structural complexity and E/I input ratio in primary hippocampal neurons and alter Ca^{2+} homeostasis and CREB1-signaling

Authors: Raphael Hesse[1], Björn von Einem[1], Franziska Wagner[1], Patricia Bott[1], Daniel Schwanzar[1], Rosemary J. Jackson[5], Karl Josef Föhr[8], Ludwig Lausser[6], Katja S. Kroker[3], Christian Proepper[4], Paul Walther[7], Hans A. Kestler[6], Tara L. Spires-Jones[5], Tobias Boeckers[4], Holger Rosenbrock[2], Christine A.F. von Arnim*[1]

[1]Department of Neurology, Ulm University, Ulm, Germany

[2]Boehringer Ingelheim Pharma GmbH & Co KG, Dept. of CNS Diseases Research, Biberach, Germany

[3]Boehringer Ingelheim Pharma GmbH & Co KG, Dept. of Drug Discovery Sciences, Biberach, Germany

[4]Institute for Anatomy and Cell Biology, Ulm University, Ulm, Germany

[5]UK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK

[6]Institute of Medical Systems Biology, Ulm University, Ulm, Germany

[7]Central Facility for Electron Microscopy, Ulm University, Ulm, Germany

[8]Department of Anesthesiology, Ulm University, Ulm, Germany

*Corresponding author

Christine A.F. von Arnim, MD
Department of Neurology
Oberer Eselsberg 45
89081 Ulm
phone: +49-731-500-63015
fax: +49-731-500-63011

E-mail: christine.arnim@uni-ulm.de (CAFvA)

Abstract

One major pathophysiological hallmark of Alzheimer's disease (AD) is senile plaques composed of amyloid β (Aβ). In the amyloidogenic pathway, cleavage of the amyloid precursor protein (APP) is shifted towards Aβ production and soluble APPβ (sAPPβ) levels. Aβ is known to impair synaptic function; however, much less is known about the physiological functions of sAPPβ. The neurotrophic properties of sAPPα, derived from the non-amyloidogenic pathway of APP cleavage, are well-established, whereas only a few, conflicting studies on sAPPβ exist. The intracellular pathways of sAPPβ are largely unknown. Since sAPPβ is generated alongside Aβ by β-secretase (BACE1) cleavage, we tested the hypothesis that sAPPβ effects differ from sAPPα effects as a neurotrophic factor. We therefore performed a head-to-head comparison of both mammalian recombinant peptides in developing primary hippocampal neurons (PHN). We found that sAPPα significantly increases axon length ($p = 0.0002$) and that both sAPPα and sAPPβ increase neurite number ($p < 0.0001$) of PHN at 7 days in culture (DIV7) but not at DIV4. Moreover, both sAPPα- and sAPPβ-treated neurons showed a higher neuritic complexity in Sholl analysis. The number of glutamatergic synapses ($p < 0.0001$), as well as layer thickness of postsynaptic densities (PSDs), were significantly increased, and GABAergic synapses decreased upon sAPP overexpression in PHN. Furthermore, we showed that sAPPα enhances ERK and CREB1 phosphorylation upon glutamate stimulation at DIV7, but not DIV4 or DIV14. These neurotrophic effects are further associated with increased glutamate sensitivity and CREB1-signaling. Finally, we found that sAPPα levels are significantly reduced in brain homogenates of AD patients compared to control subjects. Taken together, our data indicate critical stage-dependent roles of sAPPs in the developing glutamatergic system *in vitro*, which might help to understand deleterious consequences of altered APP shedding in AD patients, beyond Aβ pathophysiology.

Keywords: sAPP, AD, neuronal plasticity, neurodevelopment, CREB-1 signaling

Research highlights:

- sAPPα and sAPPβ have a critical stage-dependent role in the developing glutamatergic system *in vitro*
- sAPPβ impacts in a different manner on the developing glutamatergic system compared to sAPPα
- Effects of sAPPα are associated with CREB-1 signaling

List of abbreviations:

65 Aβ, amyloid β; AD, Alzheimer's disease; ADAM, A Disintegrin And Metalloproteinase (α-secretase);
66 APP, amyloid precursor protein; AMPA-R, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
67 receptor; BACE, β-site of APP cleavage enzyme (β-secretase); BDNF, brain-derived neurotrophic
68 factor; CNS, central nervous system; CREB, cAMP-response element binding protein; CSF,
69 cerebrospinal fluid; DIV, days in vitro; EGFP, enhanced green fluorescent protein; GABA, γ-
70 Aminobutyric acid; HRP, horse-radish peroxidase; LOAD, late-onset Alzheimer's disease; LSM, laser-
71 scanning-microscope; LTP, long-term potentiation; NMDA-R, *N*-methyl-D-aspartate receptor; PCR,
72 polymerase chain reaction; PHN, primary hippocampal neuron; PSD, postsynaptic density;
73 sAPP, soluble amyloid precursor protein; TEM, transmission electron microscopy

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88 **Introduction**

Besides being a central molecule in Alzheimer's disease (AD) pathophysiology, amyloid precursor protein (APP) and its cleavage products are known to be major players in establishing and maintaining neuronal architecture (Nicolas and Hassan, 2014). Depending on whether α- or β-secretase (BACE1) cleaves first, subsequent APP cleavage by γ-secretase fosters or precludes the generation of the neurotoxic amyloid β (Aβ) fragment (Prox et al., 2012). Alongside failure of Aβ clearance mechanisms and missense mutations in presenilin 1 or 2 genes, a shift in proteolytic APP processing towards BACE1 cleavage in AD patients that leads to gradually rising Aβ42 levels in the brain and therefore causing neuronal death is a well described hypothesis (Selkoe and Hardy, 2016). Besides the increased Aβ42 and soluble APPβ (sAPPβ) production, less sAPPα is also generated.

In contrast to the deleterious effects of Aβ on neurons, the soluble APPα cleavage product (sAPPα) is known to have neurotrophic or synaptic plasticity enhancing characteristics, as shown by increase of long-term potentiation (LTP) (Taylor et al., 2008). sAPPα, but also sAPPβ levels seem to be decreased in cerebrospinal fluid (CSF) of AD patients (Colciaghi et al., 2004; Hock et al., 1998; Lannfelt et al., 1995). BACE1 inhibition, which is a potential disease-modifying therapy for AD, leads to decreased sAPPβ levels in the CSF of treated subjects (Kennedy et al., 2016). Interestingly, a missense mutation within the gene encoding for the major α-secretase, ADAM10, resulting in attenuated activity has been recently associated with late-onset AD (LOAD) (Suh et al., 2013). Both findings can therefore lead to an imbalance of soluble APP cleavage products in the central nervous system (CNS). Until now, it has not been known how APP influences neural development and adult brain function or whether loss of these functions can account for AD pathophysiology. Hence, deciphering the physiological functions of both sAPP forms is of crucial importance.

In neuronal cell culture, it has been shown that sAPPα interacts with the p75 neurotrophin receptor to stimulate neurite outgrowth (Hasebe et al., 2013). Furthermore, sAPPα and sAPPβ decrease cell adhesion and thereby decrease dendrite outgrowth and increase axon outgrowth (Chasseigneaux et al., 2011). Neuroprotective effects are also described for sAPPα as it could be shown that it protects hippocampal neurons against Aβ induced oxidative injury (Goodman and Mattson, 1994) and proteasomal stress (Copanaki et al., 2010). Moreover, sAPPα has been shown to extenuate established synaptic and cognitive deficits in the APP/PS1ΔE9 AD mouse model (Fol et al., 2015). Another study generated a sAPPα-knock-in mouse to show that sAPPα is sufficient to rescue the abnormalities of APP-deficient mice, including reductions in brain weight and the impairment in spatial learning and LTP (Ring et al., 2007). Conversely, there is

one study published demonstrating that cleavage of sAPPβ under trophic-factor deprivation generates a cleavage product that is able to induce death receptor 6 signaling and thereby lead to cellular self-destruction (Nikolaev et al., 2009).

Generally, effects of sAPPα on neurons are well established, whereas much less is known about sAPPβ function (Chasseigneaux and Allinquant, 2012). In addition, the intracellular pathways mediating the sAPP functions are also largely unknown. Since sAPPβ derives from amyloidogenic APP cleavage, we hypothesize that sAPPβ opposes neurotrophic sAPPα effects. Therefore, to further evaluate the roles of both sAPPs in neuronal development, we performed in this study a head-to-head comparison in developing primary hippocampal neurons at different time stages.

Materials and Methods

149 **Synthesis of recombinant sAPP peptides**

150 sAPPα and sAPPβ gene fragments were amplified by PCR with human APP695 cDNA as
151 template. sAPPs were then N-terminally tagged with the APP secretory sequence, 8x histidine
152 tag, and EGFP. Constructs were subcloned in pcDNA ™5/FRT (Invitrogen, Carlsbad, CA,
153 USA) vector by NheI and ApaI restriction sites. The same construct (empty EGFP vector),
154 without sAPP sequence (APP secretory sequence, 8x histidine tag, and EGFP), was used as a
155 control peptide. For purification of sAPP and control proteins, Flp-In™HEK293 cells were
156 stably transfected (Flp-In™ system, Invitrogen, Carlsbad, CA, USA) with sAPPα, sAPPβ and
157 the EGFP construct. Ni-NTA charged agarose beads (Qiagen Hilden, Germany, #30210) were
158 added to the supernatant of the cultivated cells containing the his-tagged sAPP/EGFP fusion
159 proteins. After overnight binding, beads were washed three times with low imidazol buffer (40
160 mM imidazol) and sAPP/EGFP fusion proteins were subsequently eluted in high imidazol
161 buffer (150 mM imidazol). For buffer exchange and protein concentration eluates were pooled
162 and concentrated via 100 kDa cut-off columns (Millipore Darmstadt, Germany, #UFC810024).
163 Proteins were recovered in PBS and analyzed qualitatively and quantitatively via SDS-PAGE,
164 Western blot, BCA assay, and SimplyBlue™ SafeStain (Invitrogen, Carlsbad, CA, USA) (Fig.
165 S1).

166 **Lentiviral plasmid design and vector production**

167 To generate infectious lentiviral particles, sequences of sAPPα and sAPPβ were cloned into
168 pUltra Hot vector. sAPPα and sAPPβ gene fragments were amplified by PCR with the above-
169 mentioned sAPPα/β pcDNA ™5/FRT as template and inserted into pUltra Hot vector by AgeI
170 and NheI restriction sites. The expressed proteins were N-terminal fusion proteins with
171 mCherry. pUltra Hot is a lentiviral vector backbone for bi-cistronic expression of the gene of
172 interest and the fluorescent reporter mCherry under the control of a human ubiquitin promoter.
173 pUltra Hot was a gift from Malcolm Moore (Addgene plasmid # 24130) and served as a control
174 plasmid to induce viral stress on neurons. psPAX2 is a packaging plasmid encoding HIV-1
175 gag/pol sequences under the control of a SV40 promoter. psPAX2 was a gift from Didier Trono
176 (Addgene plasmid # 12260). pMD2.G is an envelope-expressing plasmid encoding for VSV-G
177 glycoprotein under the control of a CMV promoter. pMD2.G was a gift from Didier Trono
178 (Addgene plasmid # 12259). For the virus production, LentiX 293T cells (Takara Clontech,
179 Mountain View, CA, USA) were co-transfected (calcium phosphate transfection method) with
180 pUltra Hot, psPAX2 and pMD2.G. Six hours after transfection, the medium was changed to
181 remove transfection reagent in the conditioned medium to which the virus is secreted. 48h after

182 transfection conditioned medium was collected and filtered using a 0.2 μm sterile filter
183 (Sarstedt, Nuembrecht, Germany). Conditioned medium was transferred to 38.5 ml Beckman
184 Ultra-Clear™ tubes containing 3 ml 20% sucrose and spinned for 2.5 h at 4°C and 24,000 rpm
185 in a Beckman SW32Ti swinging bucket rotor. Supernatant was discarded and virus was
186 resuspended in DPBS, aliquoted and stored at -20°C until use.

187 **Preparation of primary hippocampal neurons**

188 Primary hippocampal neurons were prepared from brains of C57BL/6 embryonic mice (E18),
189 as described previously (Kaech and Banker, 2006). Briefly, hippocampi were dissected from
190 embryonic brains, the meninges were removed and the cells were dissociated by trypsinization
191 (0.25%) for 20 min at 37 °C. The dissociated cells were resuspended in serum-free neurobasal
192 medium (Gibco®, Invitrogen, Germany) supplemented with 10% B27 (Gibco®, Invitrogen,
193 Germany) and 0.5 mM l-glutamine and seeded into poly-l-lysine-coated culture dishes at a
194 density of $2.2x10^4$ cells per cm^2 for immunocytochemistry (grown on coverslips) and $6.6x10^4$
195 cells per cm^2 for cell lysis. After 45 min, medium was replaced completely by the same
196 medium, to reduce astroglial growth. Cells were maintained at 37°C in the presence of 5% CO_2
197 and 10% O_2 in a humidified incubator.

198 **Morphometric analysis of PHN**

199 For morphometric analyzes of PHN, neurons were treated on DIV2 with 100 nM His-EGFP-
200 sAPPα/β or the His-EGFP control peptide, fixed on DIV7 and stained with anti-MAP2 and anti-
201 tau (For antibody specification see list below). To make sure that a substantial amount of sAPPs
202 remains in the culture medium, we used 100nM His-EGFP-sAPP peptide to study long-term
203 effects on neuronal culture. This concentration was previously tested by other groups in similar
204 studies (Chasseigneaux et al., 2011). PHNs were fixed for 20 min in a 4% PFA solution in
205 DPBS. Cells were then washed three times with PBS and subsequently permeabilized and
206 blocked in Roti®-ImmunoBlock (Carl Roth, Karlsruhe, Germany) and 0.3% TritonX-100 for 1
207 h at RT. Incubation with primary antibodies was performed overnight at 4°C with gentle
208 shaking. The next day, cells were washed three times for 10 min with PBS. Incubation with
209 secondary antibodies was performed for 1 h at RT with gentle shaking. Then cells were washed
210 three times for 10 min with DPBS and embedded in Mowiol® 4-88 plus DABCO. To determine
211 primary axon length, entire neurite length and neurite number, TIFF images of stained neurons
212 were analyzed by ImageJ pluginsoftware NeuronJ. The longest tau positive neurite was
213 considered as the primary axon in DIV7 neurons and the longest beta-III-tubulin neurite was

214 considered as the primary axon in DIV4 neurons respectively. Sholl analysis (SHOLL, 1953)
215 was performed semi-automatically using ImageJ pluginsoftware Concentric Circles. Briefly, a
216 series of concentric circles was drawn around the soma with 20 µm between each circle. The
217 number of intersections were counted manually and plotted against the distance from the soma.
218 180 neurons from three independent cultures were sampled for DIV4 and DIV7 respectively.

219 **Determination of inhibitory and excitatory synapse number**

220 To determine synapse number, PHNs were fixed and stained at DIV14 using the same
221 procedure as described in Morphometric analysis of PHN in the Materials & Methods section.
222 Earlier time points were not suitable for synapse number determination due to immaturity of
223 neurons. Cells were labelled with the primary antibodies anti-Homer1 as postsynaptic marker
224 (SynapticSystems, Göttingen, Germany, #160003), anti-Bassoon as presynaptic marker (Enzo
225 Lifesciences, Lörrach. Germany, #VAM-PS003) and anti-MAP2 as dendritic marker (EnCor
226 Biotechnology, Gainesville, USA, #CPCA-MAP2) upon lentiviral mCherry-sAPP
227 overexpression (DIV2 transduction). The transduction efficiency was about 95% (data not
228 shown). As sAPP-peptides were secreted into the supernatant upon lentiviral overexpression,
229 untransduced neurons were also used for quantification. Colocalization of both synaptic
230 markers along the neurite indicate a mature glutamatergic synapse. All of these are well
231 established synapse and neurite markers used for similar assays (Goetz et al., 2006; Grabrucker
232 et al., 2011; Wang et al., 2016). Confocal images of immunostained neuronal cultures were
233 acquired with a magnification of 63x (water immersion objective, pinhole aperture 1 µm) by
234 using a Zeiss LSM 710 Meta laser scanning microscope (Carl Zeiss, Jena, Germany), as
235 described previously (Beyer et al., 2012). Quantification was performed semi-automatically by
236 using ZEN blue edition (Zeiss, Oberkochen, Germany). The criteria for determing
237 colocalization was an overlap of intensity peaks of homer1 and bassoon immunofluorescence
238 staining. The counts of glutamatergic inputs were normalized to 10µm dendrite length (MAP2
239 staining) and are indicated as numbers in the results section.

240 **Western blot analysis**

241 Before lysis, neurons pre-incubated with His-EGFP-sAPP were briefly stimulated with 10 µM
242 glutamate in wash buffer (for buffer composition see FLIPR-analysis part in Material &
243 Methods section) for 30 s. After an additional 3 min in wash buffer, cells were lysed in brain-
244 extraction buffer (BEX: 25 mM Tris pH 8.0, 20 mM NaCl, 0.6% desoxycholate, 0.6 % Igepal
245 CA-630). Cell lysates (10-20 µg total protein, determined by BCA assay) were separated by

246 lithium dodecyl sulphate (LDS)-polyacrylamide gel electrophoresis (NuPage Novex Bis-Tris
247 4-12% gradient gels, Invitrogen) prior to electrophoretic transfer onto 0.2 µm pore size
248 nitrocellulose membrane (GE Healthcare, Boston, USA, #10600001). The membranes were
249 blocked with 5% non-fat dry milk for 1 h at room temperature. Overnight incubation at 4°C
250 was performed for primary antibody binding (for used antibodies see below). The next day,
251 blots were incubated for 1 h at room temperature with horseradish peroxidase-conjugated
252 secondary antibodies prior to exposure to ECL Luminata Forte (Millipore, Darmstadt,
253 Germany, #WBLUF0100). For detection of the corresponding non-phosphorylated proteins,
254 blots were stripped with 0.1 M glycine, 1% SDS, 1% Tween-20 (pH 3.5) for 15 min at 37°C,
255 followed by blocking in 5% non-fat dry milk and incubated with the antibodies corresponding
256 to the total proteins as described above. Digitized images of the immunoblots were used for
257 densitometric measurements with ImageJ. Relative levels of phosphorylated proteins were
258 determined by normalization of the density of images from phosphorylated proteins with that
259 of the total proteins on the same blot.

260 **Antibodies**

261 The following antibodies were purchased from commercial suppliers: Western blot: anti-
262 phospho-CREB Ser^{133} (Cell Signaling Technology, clone 8763, #9198) (1:1,000), anti-
263 phospho-p44/p42 MAPK (ERK1/2) Thr^{202}/Tyr^{204} (Cell Signaling Technology, clone E10,
264 #9106) (1:1,000), anti-CREB (Cell Signaling Technology, clone 86B10, #9104) (1:1,000), anti-
265 p44/p42 (ERK1/2) (Cell Signaling Technology, clone 86B10, #9104) (1:1,000), anti-beta III
266 Tubulin (Abcam, #ab18207) (1:1,000). Immuncytochemistry (ICC): anti-VGlut1
267 (SynapticSystems, #135304) (1:400), anti-VGAT (SynapticSystems, #131011) (1:400), anti-
268 Gephrin (SynapticSystems, #147011) (1:400), anti-Homer1 (SynapticSystems, #160003)
269 (1:500), anti-Bassoon (Enzo Lifesciences, #VAM-PS003) (1:500), anti-MAP2 (EnCor
270 Biotechnology, #CPCA-MAP2) (1:500), anti-beta III Tubulin (Neuromics, #MO15013)
271 (1:500), anti-GAPDH (abcam, #ab9485). Western blot human samples: anti-human sAPPα
272 (IBL International, clone 2B3, #11088), anti-human sAPPβ (IBL International, #18957).
273 Secondary antibodies used for Western blot were HRP goat anti-mouse IgG (H+L) and HRP
274 goat anti-rabbit IgG (H+L) (Invitrogen, 1:10,000). Secondary antibodies used for ICC were
275 Alexa Fluor® 488/546/647 Goat anti-Rabbit/Mouse/Chicken IgG (H+L) (Invitrogen, 1:750).

276 **Electron-microscopical investigations**

277 Neurons were plated with a density of 6.6x10^4 cells per cm^2. After 14 days in culture, neurons
278 were fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer with 1% sucrose (pH 7.3) and
279 postfixed with 1% osmium tetroxide for 4 h. Cultures were then dehydrated through an
280 increasing propanol series, stained with 2% uranyl acetate and embedded in epoxy resin (Epon
281 812, Fluka, Germany). Ultrathin sections (70–80 nm) were cut with a diamond knife on a
282 Reichert ultramicrotome and collected on 300- mesh grids. The sections were stained with lead
283 citrate and examined at a voltage of 100 kV by using the transmission electron microscope
284 JEM-1400 (Jeol, Akishima, Japan). Images were recorded with a resolution of 2,048 × 2,048
285 pixels and a magnification of 50,000x using a Veleta digital camera (Olympus Soft Imaging
286 Solutions GmbH, Münster, Germany) and the iTEM software (Olympus Soft Imaging Solutions
287 GmbH, Münster, Germany). At least 20 images of PSDs from asymmetric synapses in different
288 cells were acquired per condition and independent experiment. Single images of the synapse
289 were taken to measure PSD thickness. The thickness was determined manually by using ImageJ
290 to measure the thickness from electron dense areas at three different locations in each PSD
291 (central, and left/right from the centre, orthogonal to the PSD). The three measured values were
292 averaged and defined as PSD thickness for the measured synapse.

293 **FLIPR-analysis**

294 Intracellular Ca^{2+} changes were monitored using the FLIPRTetra fluorometric imaging plate
295 reader (Molecular Devices, CA, USA). Before dyeloading, Neurobasal culture medium was
296 removed. The neurons were washed three times with imaging buffer (NaCl 145 mM, KCl 5
297 mM, $CaCl_2$ 2 mM, Glucose 25 mM, HEPES 12 mM, pH was adjusted to 7.4). After the last
298 wash step, neurons were loaded with 2 µM Fluo-4 diluted in imaging buffer. Neurons were
299 incubated for 45 min at 37°C. Then, neurons were washed three times with 180 µl imaging
300 buffer left after the last wash step. Neurons were incubated for 15 min with 1nM His-EGFP-
301 sAPPα, His-EGFP-sAPPβ or the control peptide His-EGFP. We decided to use 1 nM of both
302 sAPP forms and control peptide in the FLIPR experiments, since this concentration
303 (concentration response curve with 0.01, 0.1, 1 and 10 nM) was previously tested by other
304 groups in similar studies on Ca^{2+} mobilization (Furukawa et al., 1996a; Furukawa and Mattson,
305 1998). Regarding long-term studies, to make sure that a substantial amount of sAPPs remains
306 in the culture medium over the time course of the experiment, we used the supra-effective
307 concentration of 100nM sAPP peptide to the study long-term effects of sAPPs on neuronal
308 culture. This experiment was not aimed at defining exactly the minimal effective concentration,
309 but rather to investigate mechanistically the long-term effects of sAPPs. Further, this

310 concentration was previously tested successfully by other groups in similar experiments
311 (Chasseigneaux et al., 2011). After recording the baseline for 10 s, 20 µl imaging buffer
312 containing 100 µM glutamate (final concentration in wells was 10 µM) was added to the wells
313 and the kinetic of the Ca^{2+} responses was measured on the FLIPR device for evaluation of
314 intrinsic compound activity.

315 **Synaptoneurosome preparation**

316 Synaptoneurosomes and homogenates were prepared as described in Tai et al. 2012 (Tai et al.,
317 2012) using human end stage AD and control brain tissue provided by the Edinburgh Brain
318 Bank. In brief, approximately 300 mg of Brodmann area 41/42 was homogenized in 1 ml of ice
319 cold Buffer A (25 mM HEPES pH 7.5, 120 mM NaCl, 5 mM KCl, 1 mM $MgCl_2$, and 2 mM
320 $CaCl_2$), supplemented with 2 mM dithiothreitol (DTT), protease inhibitors (roche complete
321 mini) and phosphatase inhibitors (Millipore, 524629). The homogenate was filtered through 2
322 layers of 80 µm nylon filter (NY8002500, Millipore), and a 200 µl aliquot of this was saved as
323 the crude homogenate. The saved aliquot was mixed with 140 µl water, 60 µl of 10% SDS and
324 boiled for 5 minutes. To prepare the synaptoneurosomes the remainder of the homogenate was
325 filtered through a 5 µm filter (SLSV025NB, Millipore) and centrifuged at 1,000 g for 5 minutes.
326 The supernatant was removed and the pellet was suspended in Buffer A and centrifuged again
327 (1,000 g for 5 min). The supernatant was again removed and the resulting synaptoneurosome
328 pellet was suspended in 400 µl of Buffer B (50 mM Tris [pH 7.5], 1.5% SDS, and 2 mM DTT)
329 and boiled for 5 min.
330
331 Protein concentration was determined using a BSA assay (ThermoFisher, 23225) and 5 mg of
332 protein from either synaptoneurosome or crude homogenate was loaded onto NuPAGE 4-12%
333 Bis-Tris precast polyacrylamide 15 well gels (Invitrogen, Paisley, UK) along with molecular
334 weight marker (Li-Cor, Cambridge, UK). Proteins were electro-transferred to nitrocellulose
335 membrane (Bio-Rad, Hemel Hempstead, UK). Membranes were blocked using Odyssey
336 Blocking Buffer (927-40000, LI-COR) diluted 1:1 in PBS. Primary antibodies were incubated
337 overnight in block with gentle shaking. Proteins were visualized on an Odyssey infrared system
338 using the appropriate 680 and 800 IR dye secondary antibodies (1:50,000, LI-COR Biosciences)
339 and were analyzed using Odyssey software (LI-COR Biosciences). Patient demographic data
340 are depicted in Table S1.

341 **Data analysis**

All statistical analyzes were carried out by GraphPad Prism 6.05. Data was tested for Gaussian distribution by the D'Agostino-Pearson omnibus normality test. For comparison of two groups, a Students *t*-test was used. When data was not normally distributed, the ranked values of two groups were tested for significant differences using a Mann-Whitney *U*-test. A Kruskal-Wallis test and Dunn's post hoc test for multiple comparisons were used when more than two groups were tested for significant differences. Statistically significant differences in FLIPR analysis among different groups were determined using Two-Way ANOVAs with a Dunnett's post-hoc test for multiple comparisons. The results are expressed as median (25th–75th percentile).

As an integrative analysis over different distances the results of the Sholl analysis were analyzed in comparative regression experiments (Dünkler et al., 2015). A global regression model fitted to the samples of both groups (treated/untreated) was tested against a pair of group-wise models fitted individually to the curves treated or the untreated samples. The significance of a difference between the treated group and the untreated group was determined by a comparison of the least square errors of the global model and the pair of individual models (F-Test) (Lomax et al., 2012; Motulsky and Ransnas, 1987). The model types were selected via the Akaike information criterion (Burnham et al., 2002). They were chosen from a set of 10 predefined model types. The corresponding software (CuCompare) is available at http://sysbio.uni-ulm.de/soft/CuCompare.

Results

369 **sAPP treatment of PHN affects neuronal morphology and complexity in a stage-**
370 **dependent manner**

371 To determine the differential effects of sAPPs on neuronal morphology and branching we
372 produced recombinant proteins of human sAPPα695 and sAPPβ695 in HEK293 cells. These
373 bear all post-translational modifications observed in eukaryotic cells. PHNs were treated at
374 DIV2 with 100 nM His-EGFP-sAPPα or His-EGFP-sAPPβ and fixed and immunostained with
375 MAP-2 and Tau at DIV7 or β-III-tubulin at DIV4 respectively. His-EGFP-sAPP administration
376 (100 nM) to PHN at DIV2 with fixation at DIV 4 did not lead to altered primary axon length
377 (Fig. 1A), entire neurite length (Fig. 1B), and neurite number (Fig. 1C). The median lengths,
378 25th and 75th percentiles are depicted in table 1.

379 When PHNs were treated with the same concentration of His-EGFP-sAPP at DIV2 and fixed
380 at DIV7, the median primary axon length was increased significantly by 21.5% upon His-
381 EGFP-sAPPα treatment (p = 0.0002) but not upon His-EGFP-sAPPβ treatment (Fig. 1 D).
382 Morphometric analysis also revealed a significant increase in median neurite length per neuron
383 ($p < 0.0001$) (Fig. 1E) and also in median neurite number by 50% upon His-EGFP-sAPPα and
384 33.3% upon His-EGFP-sAPPβ treatment ($p < 0.0001$) (Fig. 1F). The median lengths, 25th and
385 75th percentiles are depicted in table 1. The significant increase in neurite number upon His-
386 EGFP-sAPPα and His-EGFP-sAPPβ treatment raised the question if there is also alteration in
387 neuritic ramification. To determine neuritic complexity at DIV7, Sholl analysis was performed.
388 We plotted the number of intersections of neurites with each circle against the distance from
389 the cell body (see scheme in Fig. 1G). This extensive analysis revealed a significant increase in
390 neuritic arborization upon His-EGFP-sAPPα and His-EGFP-sAPPβ treatment (Fig. 1H)
391 significant for distances from soma from 20 µm to 200 µm, $p < 0.05$). Further analysis revealed
392 a distinct pattern of arborization for His-EGFP-sAPPα and His-EGFP-sAPPβ, with increased
393 branching close to the soma for His-EGFP-sAPPα. Exemplary images of analysed neurons are
394 shown in Fig. S2.

Table 1. Summarized morphological analysis of primary hippocampal neurons

	4 DIV ctrl	**4 DIV sAPPα**	**4 DIV sAPPβ**
Axon length [nm]	113.1 (86.14 – 146.5)	109.3 (77.41 – 139.2)	113.5 (35.19 – 153.8)
Neurite length [nm]	226.2 (182.8 – 268.4)	220.0 (174.3 – 277.6)	242.6 (191.8 – 295.6)

Neurite number	4 (3 – 5)	4 (3 – 5)	4 (3 – 5)
	7 DIV control	**7 DIV sAPPα**	**7 DIV sAPPβ**
Axon length [nm]	324.4 (255.2 – 438.5)	394.1 (322.6 – 470.7)*	352.2 (283.1 – 445.3)
Neurite length [nm]	1234.0 (868.8 – 1680.0)	1696.0 (1430.0 – 2174.0)*	1622.0 (1303.0 – 2095.0)*
Neurite number	12 (9 – 16)	18 (14 – 23)*	16 (12.25 – 22)*

Axon lengths, neurite lengths and neurite numbers are indicated as median (25th-75th percentile). Statistical significance is marked by an asterisk. *$p < 0.0001$, One-Way ANOVA, Kruskal-Wallis test, Dunn's post-hoc test.

Advanced glutamatergic synaptic architecture upon sAPP overexpression

To test the hypothesis that the increased neuritic arborization of PHN upon His-EGFP-sAPP treatment at DIV7 (first mature synapses observed) is associated with an increased function of glutamatergic synapses, we determined the synapse number upon lentiviral sAPP overexpression and compared them with control neurons at DIV14, where synaptic maturation is well established. Use of the lentiviral expression system ensured a stable and brief secretion of sAPP to supernatant of neuronal cell culture from DIV2 to DIV14. Secretion of sAPP peptides to neuronal cell culture supernatant was verified by Western blot (Fig. S1). Using double staining for Homer1 (postsynaptic marker) and Bassoon (presynaptic marker) at DIV 14, we were able to discriminate immature from mature glutamatergic synapses (Grabrucker et al., 2009). Colocalization of Homer1 and Bassoon indicated a fully developed excitatory synapse (Fig. 2A). We observed that 75% more mature glutamatergic synapses were developed until DIV14, when mCherry-sAPPα was overexpressed ($p < 0.0001$) and 25% more mature synapses when mCherry-sAPPβ ($p < 0.0001$) was stably secreted for 12 DIV in primary hippocampal neurons. The median number of mature glutamatergic synapses at DIV14 was 1.6 (1.2–2.0) in the control condition, 2.8 (2.1–3.5) upon mCherry-sAPPα overexpression and 2.0 (1.6–2.3) upon mCherry-sAPPβ overexpression (Fig. 2B). mCherry-sAPPα as well as mCherry-sAPPβ overexpression resulted in a marked rightward shift in the frequency distribution of synapse numbers, indicating an increased number of colocalizations (Fig. 2C).

To test the hypothesis that increased sAPP levels, leading to an increased number of glutamatergic synapses, also lead to alterations in the subsynaptic architecture, we determined PSD layer thickness from asymmetric synapses in mCherry-sAPP-overexpressing neurons by

420 electron microscopy. Asymmetric synapses were distinguished from symmetric synapses. The
421 former are excitatory in function and are formed by axon terminals that contain spherical
422 synaptic vesicles and an electron-dense PSD (Fig. 2D, asterisks mark PSDs). We observed that
423 PSDs of neurons exposed to higher extracellular sAPPα levels showed a 27.4% increase in
424 median layer thickness compared to control neurons. PSDs of mCherry-sAPPβ-overexpressed
425 neurons were not significantly changed. The median PSD strength of neurons was 14.6 nm
426 (10.5–17.6 nm) in control, 18.6 nm (14.1–23.0 nm) after treatment with mCherry-sAPPα and
427 14.0 nm (10.9–17.1 nm) after treatment with mCherry-sAPPβ (Fig. 2E). Increased exposure to
428 mCherry-sAPPα led to a homogenous rightward shift in frequency distribution of PSD layer
429 thickness (Fig. 2F).

430

431 **Increased neuritic arborization is associated with higher levels of activated markers of**
432 **neuronal activity**

433 Since it has been previously described that sAPP levels are altered during aging and disease,
434 we hypothesized that sAPPs can influence neuronal activity of maturated PHNs. To test,
435 whether mature hippocampal neurons are responsive to sAPP effects mediated by the
436 glutamatergic system in principal, neurons were loaded with a Ca^{2+}-sensitive dye (Fluo4) and
437 incubated for 15 min with 1 nM of His-EGFP control peptide, His-EGFP-sAPPα or His-EGFP-
438 sAPPβ at DIV14. Subsequent Ca^{2+}-imaging by a FLIPR system revealed that both His-EGFP-
439 sAPPα and His-EGFP-sAPPβ administration increased glutamate (stimulation with 10 µM
440 glutamate) induced cytoplasmatic $Ca2^{+}$ levels in mature hippocampal neurons (Fig. 3A).

441 Next we tested whether downstream Ca^{2+} signaling is also affected by long-term application of
442 His-EGFP-sAPP peptides. We administered 100 nM His-EGFP control peptide, His-EGFP-
443 sAPPα or His-EGFP-sAPPβ to primary hippocampal neurons at DIV2 (lentiviral mCherry-
444 sAPP overexpression for DIV14 neurons). At DIV4, DIV7 or DIV14, hippocampal neuronal
445 cultures were briefly stimulated with 10 µM glutamate for 30 s to induce neuronal activity in
446 the glutamatergic system. Subsequent determination of p-ERK2 and p-CREB1 levels revealed
447 that hippocampal cell cultures treated with 100 nM His-EGFP-sAPPα from DIV2 to DIV7 show
448 significantly higher levels of phosphorylated ERK2 (78.4% increase, $p = 0.02$) (Fig. 3B) and
449 CREB1 (300.1% increase, $p = 0.01$) (Fig. 3C) determined by Western blot (normalized to total
450 levels or ERK2 or CREB1 respectively). By contrast, we did not see changes induced by His-
451 EGFP-sAPP administration upon glutamate stimulation of DIV4 or DVI14 neuronal cell

452 cultures compared to treatment with the His-EGFP control peptide (Fig. 3B, C). To further
453 elucidate the short-term effects of His-EGFP-sAPPα and His-EGFP-sAPPβ on the
454 phosphorylation of CREB, SH-SY5Y cells were transfected with a FRET-based CREB1
455 biosensor (ICAP) and pre-treated with 1nM His-EGFP-sAPPα and His-EGFP-sAPPβ.
456 Ratiometric analysis of the FRET fluorophores revealed a significant increase in CREB1
457 phosphorylation upon His-EGFP-sAPPα treatment 5 mins after glutamate stimulation (Fig. S3
458 A). CREB1 phosphorylation level was unchanged upon His-EGFP-sAPPβ treatment (Fig. S3
459 B).

460

461 **sAPP overexpression led to advanced glutamatergic architecture at DIV14 comparable to**
462 **control treated DIV21 neurons but it suppresses the formation of GABAergic inputs**

463 sAPP effects may be limited to a subpopulation of synaptic terminals. We therefore asked to
464 what extent glutamatergic, as opposed to GABAergic, synaptic terminals benefited from the
465 presence of sAPPs in supernatant of neuronal culture medium. To answer this question, we
466 transduced PHNs at DIV2 with mCherry-sAPPα-, mCherry-sAPPβ- or a mCherry-control-
467 lentivirus. At DIV14 and DIV21, we counted VGlut1 positive puncta along the dendrite as
468 markers for the excitatory presynapse (Fig. 4A). VGAT1 was used as a marker for inhibitory
469 synapses (Fig. 4C). Upon mCherry-sAPPα overexpression, DIV14 PHNs showed a significant
470 increase in VGlut1 positive puncta (20%, $p < 0.0001$) normalized to 10 µm dendrite length
471 compared to overexpression of the mCherry control construct (Fig. 4B). When mCherry-sAPPβ
472 was overexpressed in primary neurons until DIV14, the median number of VGlut1 positive
473 puncta was elevated by 20% ($p < 0.0001$). The median quantity of VGlut1 positive puncta at
474 DIV14 was 1.5 (1.2 – 1.7) in the control, 1.8 (1.5–2.1) in the mCherry-sAPPα overexpressing
475 neurons and 1.8 (1.5 – 2.1) upon mCherry-sAPPβ overexpression in primary hippocampal
476 neurons.

477 In contrast to glutamate-releasing presynapses, GABA-releasing terminals are inhibitory in
478 function. To test whether synaptogenesis in general is elevated in the presence of exogenous
479 sAPP, we next determined the number of GABA- versus glutamate-releasing terminals in
480 DIV14 neurons in mCherry-sAPP-overexpressing hippocampal neurons (Fig. 4C). Upon
481 mCherry-sAPPα overexpression, 32% less GABAergic terminals were developed compared to
482 overexpression of the control construct ($p < 0.0001$). The number of GABA-releasing
483 presynapses was also significantly reduced by 28% when developing neurons were exposed to

484 mCherry-sAPPβ compared to the control peptide ($p < 0.0001$) (Fig. 4D). The median of
485 absolute inhibitory presynapses were 1.0 (0.8–1.2) after mCherry-sAPPα, 1.0 (0.8–1.3) after
486 mCherry-sAPPβ and 1.4 (1.2–1.7) upon mCherry-control construct overexpression. The
487 calculated ratio of glutamatergic to GABAergic synaptic terminals was significantly increased
488 by 76% upon mCherry-sAPPα and 72% after mCherry-sAPPβ overexpression ($p < 0.001$) (Fig.
489 4E).

490 To further test the hypothesis that neuronal development *in vitro* is advanced resulting from a
491 neuronal network exposed to elevated sAPP levels, we transduced PHNs at DIV2 with a
492 mCherry-control-lentivirus and counted VGlut1 and VGAT at DIV21 and compared them with
493 DIV14 mCherry-sAPP-overexpressing neurons. We found that neurons overexpressing the
494 control construct from DIV2 to DIV21 showed 27% ($p < 0.0001$) more VGlut1, but no
495 significant change in the number of VGAT positive puncta compared to neurons overexpressing
496 the control construct from DIV2 to DIV14 (Fig. 4B,D). The median count of VGlut1 positive
497 puncta at DIV21 was 1.9 (1.6–2.2) (Fig. 4B) and 1.6 (1.3–1.9) (Fig. 4D) for VGAT positive
498 puncta upon overexpression of the control construct. A proposed model of how sAPP could
499 affect synapse development *in vitro* is depicted in Fig. 4F.

500

501 **sAPPα is decreased in AD brains and can be detected in human synaptoneurosomes**

502 Since we were able to show that sAPPα and sAPPβ have crucial functions in the development
503 of the glutamatergic system *in vitro* and activity of the major α-secretase ADAM10 and BACE1
504 activity seem to be altered in LOAD patients, we next asked whether sAPP levels are altered in
505 homogenates and synaptoneurosomes of human *post-mortem* tissue of AD patients and control
506 subjects. To do so, we enriched synaptoneurosomes from BA41/42 of end stage brain tissue by
507 a previously reported method (Tai et al., 2012). Western blot analysis with a human sAPPα-
508 specific antibody revealed that sAPPα is significantly decreased by about 53% in brain
509 homogenate of AD patients compared to control subjects (Fig. 5A, $p = 0.007$). We further
510 observed a tendency of reduced sAPPα levels in synaptoneurosomes of AD patients (Fig. 5B,
511 $p = 0.128$). We also tested if sAPPβ is detectable in human brains with a human sAPPβ specific
512 antibody. We were not able to detect full length sAPPβ in human brain homogenates or
513 synaptoneurosomes, but cleavage fragments (Fig. S4). Therefore, we did not quantify these
514 Western blots.

Discussion

535 Considering that levels of the soluble APP ectodomains, released by initial ADAM-10 or
536 BACE1 cleavage, are altered in AD patients (Cuchillo-Ibañez et al., 2015; Holsinger et al.,
537 2004; Lannfelt et al., 1995; Palmert et al., 1990; Zetterberg et al., 2008), the natural *in vivo*
538 function of sAPPs in the CNS are of pivotal interest.

539 In this study, we investigated the impact of sAPPs on the glutamatergic system and the
540 accompanying morphological changes in hippocampal neuronal cell culture side by side. We
541 found that both sAPPβ and sAPPα stimulate the glutamatergic system in hippocampal neurons
542 *in vitro* and regulate neuronal development and synapse formation in a stage-dependent fashion.

543 Our study reports several important findings. First, both sAPPβ and sAPPα affect neuronal
544 morphology and complexity in a stage-dependent manner in PHNs. Having structurally and
545 functionally different processes that act as communication relay in the CNS, neurons are one
546 of the most highly polarized cell types in nature (Takano et al., 2015). As in our study, DIV4
547 PHNs do not show morphological differences when analyzed by determining the axon length,
548 entire neurite length and neurite number. Therefore, sAPPs should not interfere with early
549 stages in neuronal development *in vitro*. The observation that His-EGFP-sAPPβ-treated
550 neurons showed different effects in Sholl analysis compared to His-EGFP-sAPPα-treated
551 neurons, suggests that different receptors may be involved in mediating sAPPα and sAPPβ
552 effects. Considering that, in our study, sAPPs interfered with intermediate stages (DIV7), but
553 not with early stages (DIV4) of neuronal development in cell culture, we can assume that sAPPs
554 affect dendritic development rather than axon specification. Since we further showed that
555 sAPPs impact on glutamate signaling, it seems likely that functions are mediated by modulation
556 of a subset of distinct glutamate receptors that are differentially expressed during PHN
557 development *in vitro* (Janssens and Lesage, 2001) and *in vivo* (Luján et al., 2005). A recent
558 study by Hasebe et al. revealed that sAPPα promotes neurite outgrowth in stage 1 neurons (24
559 h after plating) (Hasebe et al., 2013). This finding contradicts our results to some extent, but
560 differences might be explained by the use of another neuronal culture system (cortical neurons
561 instead of hippocampal neurons). In fact, in line with our findings, Chasseigneaux et al. were
562 able to demonstrate that sAPPα increases axon length in primary neurons (Chasseigneaux et
563 al., 2011). In contrast to our findings, they observed a decrease in dendrite outgrowth. The
564 difference could be explained by the earlier stage (DIV5 neurons from E16 mice vs. DIV7
565 neurons from E18 mice) they examined or the investigation of cortical neurons instead of
566 hippocampal neurons and the utilization of another mouse strain (Swiss instead of C57BL/6).

567 Our results are also in agreement with a previous study showing that sAPPα enhances axon
568 growth (Young-Pearse et al., 2008).

569 Second, in this study, we show that mCherry-sAPP overexpression in PHNs results in increased
570 glutamatergic synaptic architecture in DIV14 neurons. For precise functioning of the
571 mammalian brain, it is crucial that neuronal contacts are formed properly and maintained in the
572 long term, if needed. Since synaptogenesis in PHNs is dependent on neuronal activity and
573 connectivity, amongst others, we next asked whether long-term exposure of sAPPs to PHNs
574 impacts synaptogenesis and the formation of subsynaptic structures like the PSD. In line with
575 our findings, that both mCherry-sAPPα and mCherry-sAPPβ overexpression led to a higher
576 number of mature glutamatergic synapses in PHNs, Bell et al. reported that ADAM-10-
577 overexpression in mice increased the brain sAPPα levels and the number of presynaptic bouton
578 densities (Bell et al., 2008). Other work showed that infused sAPPα increased memory retention
579 and synaptic density in the frontoparietal cortex of rats (Roch et al., 1994). The process of
580 synapse formation involves axo-dendritic contact after axon extension, presynaptic and
581 postsynaptic differentiation, synaptic maturation, pruning and maintenance (Johnson-
582 Venkatesh and Umemori, 2010). At which stage sAPPs enhance synaptogenesis is not clear yet
583 and remains to be answered. The observation that mCherry-sAPPα exposure leads to increased
584 layer thickness of PSDs in PHN synapses, agrees with several studies investigating the effects
585 of sAPPα on synaptic transmission and LTP (Taylor et al., 2008) or the ability of sAPPα to
586 rescue synaptic deficits in different APP transgenic mice (Fol et al., 2015; Hick et al., 2015;
587 Ring et al., 2007). Claasen et al. further showed, that sAPPα upregulates synaptic protein
588 synthesis by a proteinkinase G-dependent mechanism in synaptoneurosomes prepared from rat
589 hippocampi (Claasen et al., 2009). Based on these results, we can conclude that the sAPP-
590 induced extended neuritic arborization at DIV7 ends up in an advanced synaptic architecture of
591 glutamatergic synapses at later stages (DIV14) of neuronal development *in vitro*.

592 Third, we demonstrated that increased neuritic arborization is associated with higher levels of
593 activated markers of neuronal activity. Development of the neuritic arbor and synaptogenesis
594 are, *inter alia*, dependent on neuronal activity. To that end, we tested the hypothesis that the
595 more sophisticated arborization at DIV7 and the advanced synaptic architecture at DIV7 upon
596 sAPP exposure is associated with neuronal activity. We first tested whether sAPPs influence
597 glutamate-evoked Ca^{2+} signals in mature PHNs. By showing that both His-EGFP-sAPPα and
598 His-EGFP-sAPPβ (15 min preincubation) increase free intracellular Ca^{2+} levels upon glutamate
599 stimulation, we concluded that sAPPs modulate glutamate sensitivity of PHNs in a short-term

600 response. Given that a 15 min preincubation with sAPPs was enough to alter glutamate
601 sensitivity of PHNs, a mobilization of the synaptic AMPA-R pool mediated by sAPPs is more
602 likely than a transcription-based response. To obtain a more detailed picture of how sAPPs
603 modulate neuronal plasticity on a molecular level, we next asked whether glutamate-activated
604 synaptic plasticity-dependent downstream targets of Ca^{2+} signaling are also affected by His-
605 EGFP-sAPP exposure to neurons. Downstream components of Ca^{2+} are, amongst others,
606 mitogen-activated protein kinase 1 (ERK2) and the transcription factor cyclic AMP-responsive
607 element-binding protein 1 (CREB1). Hence, we tested whether His-EGFP-sAPPs modulate
608 ERK2 and CREB1 phosphorylation in glutamate stimulated PHNs at different stages of
609 development (DIV4, DIV7, DIV14). When PHNs were briefly stimulated with glutamate, we
610 detected increased levels of p-ERK2 as well as p-CREB1 upon long-term His-EGFP-sAPPα
611 exposure to neurons until DIV7. By contrast, we did not see any differences in p-ERK2 or p-
612 CREB1 levels at DIV4 or DIV14 glutamate-stimulated PHNs when exposed to His-EGFP-
613 sAPPs compared to control. We concluded that a peak level of phosphorylated LTP-dependent
614 kinases at DIV7 leads to increased neuritic arborization and subsequently to an advanced
615 development of glutamatergic synapses. Unchanged levels of activated ERK2 and CREB1 at
616 DIV4 upon His-EGFP-sAPP treatment are associated with unaltered neuritic morphology.
617 Long-term His-EGFP-sAPP exposure to neurons did not affect p-ERK2 or p-CREB1 levels
618 when the neuronal network was stimulated at DIV14. The latter could be a ceiling effect or a
619 compensatory mechanism to protect neurons from overexcitation. To determine short term
620 effects of sAPPs, we analyzed time resolution of sAPP treatment immediately after treatment
621 in SH-SY5Y cells. We found an immediate response on CREB1 phosphorylation upon His-
622 EGFP-sAPPα treatment. These results are in line with a study by Ryan et al. showing that
623 sAPPα induces time-dependent changes in gene expression in the rat hippocampus, amongst
624 other downstream targets of CREB1 (Ryan et al., 2013). Our results further confirm recent
625 findings revealing that sAPPα and sAPPβ promote Egr1/ERK1 signaling leading to enhanced
626 axon outgrowth *in vitro* (Chasseigneaux et al., 2011). Moreover, a study by Rohe et al. showed
627 that increased levels of sAPP correlated with pro-found stimulation of neuronal ERK signaling
628 (Rohe et al., 2008). Since we have shown that sAPPs modulate glutamate induced CREB1
629 activation, a direct modulation of one or more distinct glutamate receptor seem to be likely.
630 However, which of glutamate receptor (or subunit composition) is modulated by sAPPs remains
631 to be determined. At least, one study by Taylor et al. showed that sAPPα regulates hippocampal
632 NMDA-receptor function (Taylor et al., 2008).

633 Fourth, mCherry-sAPP overexpression led to advanced glutamatergic architecture at DIV14
634 comparable to control-treated DIV21 neurons, but it suppresses the formation of GABAergic
635 inputs. Since we showed, that both sAPPs positively regulate neuritic arborization and synapse
636 formation, we determined whether the sAPP effects are a mere mechanism of advanced
637 development. Therefore, we compared the number of inhibitory and excitatory synaptic inputs
638 of mCherry-sAPP-treated PHNs at DIV14 with control treated DIV21 neurons. We found that
639 the number of excitatory synaptic inputs of DIV14 PHNs exposed to mCherry-sAPPs was
640 comparable with control-treated DIV21 neurons. In contrast, the number of inhibitory inputs in
641 hippocampal cell culture was not decreased in the control when comparing DIV21 with DIV14.
642 We show here for the first time that the number of inhibitory synaptic inputs, determined by
643 VGAT immunostaining, is decreased when comparing control treated DIV14 inhibitory inputs
644 with DIV14 mCherry-sAPP-treated inhibitory inputs. Therefore, we concluded that sAPP
645 effects are not merely resulting from advanced neuronal development, but rather modulate the
646 ratio of excitatory to inhibitory inputs. Since proper formation and function of neuronal circuits
647 depends on the balance of inhibitory and excitatory mechanisms, this is an important finding.
648 To rule out that the decrease in GABAergic input is a consequence of cell death, we tested if
649 sAPPs impact on cell viability by the MTT assay. We found no impact of sAPP preparations
650 on cell viability, even at high concentrations (data not shown). Interestingly, genes related to
651 GABAergic signaling like glutamate decarboxylase 1 and 2 (GAD) or somatostatin (Sst)
652 possess CREB1 binding sites in their promotor regions (Zhang et al., 2005). Furthermore, in
653 patients suffering from autism spectrum disorders (ASDs), an imbalance in
654 GABAergic/glutamatergic inputs was observed (El-Ansary and Al-Ayadhi, 2014) and
655 increased levels of sAPPα were described in the CSF of ASD patients (Ray et al., 2011).
656 Whether these findings correlate statistically significantly or are causative for pathophysiology
657 remains to be determined. Our finding that neuronal complexity, synapse maturation and E/I
658 balance are increased in PHNs upon sAPP exposure are in line with several studies focusing on
659 BDNF effects on developing neurons (Ji et al., 2010; Singh et al., 2006). This raises the question
660 of whether sAPP can directly/indirectly modulate or bind to TrkB receptors to induce BDNF-
661 like effects. Further studies are needed to shed light on this hypothesis.

662 Fifth, in almost all our assays assessing the effects of sAPPs on glutamatergic development, we
663 observed that sAPPβ effects are similar to neurotrophic sAPPα effects. These findings disprove
664 our hypothesis that sAPPβ differs from the neurotrophic effects on the developing
665 glutamatergic system of sAPPα. Differences between sAPPα and sAPPβ were seen in the Sholl
666 analysis that revealed a distinct pattern of ramification for sAPPα and sAPPβ, with increased

667 branching close to the soma for sAPPα. In contrast to sAPPα-treated neurons, sAPPβ exposure
668 did not lead to axon elongation. Furthermore, sAPPβ-treated neurons did not show increased
669 PSD layer thickness or ERK phosphorylation, whereas sAPPα-treated neurons did.
670 Interestingly, a study by Furukawa et al. could show that sAPPα was approximately 100-fold
671 more potent than sAPPβ in protecting hippocampal neurons against excitotoxicity, Aβ toxicity,
672 and glucose deprivation (Furukawa et al., 1996b). The main domains described to mediate the
673 neurotrophic effects of sAPPα are shared by sAPPβ, except for the last 16 c-terminal amino
674 acids. This would favor a model where the common parts of sAPPα and sAPPβ mediate the
675 observed functions. Other functions might be affected differentially as a study by Peters-Libeu
676 et al. indicated that, despite the large sequence homology between both sAPPs, the folding is
677 different, leading to different effects on APP cleavage by BACE1 (Peters-Libeu et al., 2015).
678 If sAPPα and sAPPβ bind (e.g. depending on their folding) to the same or distinct receptors to
679 mediate their functions remains elusive.

680 Finally, we observed that sAPPα is significantly decreased in human AD brains and detectable
681 in human synaptoneurosomes compared to control subjects. Until now, almost all studies
682 investigating the protein levels of sAPPs in human CNS used CSF as sample material
683 (Colciaghi et al., 2004; Hock et al., 1998; Lannfelt et al., 1995; Palmert et al., 1990). We show
684 here for the first time, that sAPPα is significantly decreased in AD brains and abundant in
685 human synaptoneurosomes in AD patients and control subjects. Moreover, we observed a
686 reduction in sAPP levels in human synaptoneurosomes from AD patients compared to control
687 subjects by trend. Both confirmed studies which found decreased sAPPα levels in CSF of AD
688 patients (Colciaghi et al., 2004; Hock et al., 1998; Lannfelt et al., 1995; Palmert et al., 1990).
689 The sAPPβ antibody used in our study was not suitable to detect full length sAPPβ. For this
690 reason, it remains to be determined if sAPPβ is also altered in AD brains. Since we
691 demonstrated several crucial effects of sAPPα and sAPPβ in neuronal development, reduced
692 sAPPα levels in brains of AD patients could have deleterious effects beyond Aβ
693 pathophysiology, e.g. due to decrease of specific neurotrophic or neuroprotective mechanisms.
694 Furthermore, altered sAPP levels in the developing brain might contribute to selective
695 vulnerability of hippocampal neurons and therefore accelerating disease progression, e.g. by
696 interfering with neuronal cell-type specification mechanisms (Götz et al., 2009). Disturbances
697 in adult neurogenesis might be another explanation of how altered sAPP levels can account for
698 AD pathophysiology (Lazarov and Demars, 2012; Lazarov and Marr, 2010; Wang et al., 2014).

Taken together, our study confirmed previous findings describing neurotrophic effects for sAPPα and revealed that human recombinant sAPPβ effects resemble sAPPα effects, but to a lesser extent. We further showed that neurotrophic effects of both sAPPs in early PHN development are associated with advanced glutamatergic development and revealed that sAPPs lead to altered E/I balance in mature hippocampal neurons (Fig. 4F). Synaptic impairments observed in AD patients might be a consequence not only of Aβ accumulation, but also to the loss of synapse-promoting abilities of sAPPα and sAPPβ. Our data indicate critical stage-dependent roles of both sAPPs in the developing glutamatergic system *in vitro*, and thus lead to a better understanding of deleterious consequences of altered APP shedding in AD patients and BACE-1 inhibitor recipients.

Acknowledgments

Ethics approval and consent to participate: Use of human tissue for post-mortem studies has been reviewed and approved by the Edinburgh Brain Bank ethics committee and the ACCORD medical research ethics committee, AMREC (ACCORD is the Academic and Clinical Central

Office for Research and Development, a joint office of the University of Edinburgh and NHS Lothian - Ethics approval reference 15-HV-016). The Edinburgh Brain Bank is a Medical Research Council funded facility with research ethics committee (REC) approval (11/ES/0022). Tissue from 14 donors was used for this study and their details are found in Table S1.

Consent for publication: Not applicable.

Competing interests: CAFvA received honoraria from serving on the scientific advisory board of Nutricia GmbH (2014) and Hong Kong University Research Council (2014) and has received funding for travel and speaker honoraria from Nutricia GmbH (2014), Novartis Pharma GmbH (2011), Lilly Deutschland GmbH (2013), Desitin Arzneimittel GmbH (2014) and Dr. Willmar Schwabe GmbH &Co. KG (2014) as well as research support from Roche Diagnostics GmbH (2013–2015), Biologische Heilmittel Heel GmbH (2012) and ViaMed GmbH (2011–2014).

HR and KSK are employees of Boehringer Ingelheim Pharma GmbH & Co KG.

All authors report no conflict of interest.

Funding: This work was supported by the Boehringer Ingelheim Ulm University BioCenter (BIU) project N7. Further support was provided by Alzheimer's Research UK, the European Research Council, a University of Edinburgh Wellcome Trust Institutional Strategic Support Fund, the UK Dementia Research Institute and an anonymous donor.

Authors contributions: Study concept and design: CAFvA, HR, RH, BvE, DS, CS; acquisition of data: RH, FW, PB, RJJ, PW; analysis and interpretation of data: RH, BvE, LL, HK, CAFvA; drafting of the manuscript: RH, CAFvA, HR; critical revision of the manuscript for important intellectual content: CAFvA, HR, TMB, KSK, TSJ, HK, KF, CP

Acknowledgements: The authors thank Ulrike Formentini (Ulm University) and Dirk Gester (Boehringer Ingelheim) for their help in preparation of primary hippocampal neurons and FLIPR-imaging and Renate Kunz (Central facility for electron microscopy Ulm University) for preparation of EM samples. The authors also thank the MRC Edinburgh Brain and Tissue Bank as well as all donors and their families.

Authors' information: [1]Department of Neurology, Ulm University, Ulm, Germany; [2]Boehringer Ingelheim Pharma GmbH & Co KG, Dept. of CNS Diseases Research, Biberach, Germany; [3]Boehringer Ingelheim Pharma GmbH & Co KG, Dept. of Drug Discovery Sciences, Biberach, Germany; [4]Institute for Anatomy and Cell Biology, Ulm University, Ulm, Germany; [5]UK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK; [6]Institute of

757 Medical Systems Biology, Ulm University, Ulm, Germany; [7]Central Facility for Electron
758 Microscopy, Ulm University, Ulm, Germany; [8]Department of Anesthesiology, Ulm University,
759 Ulm, Germany
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782

783 **References**

784 Bell, K.F., Zheng, L., Fahrenholz, F., Cuello, A.C., 2008. ADAM-10 over-expression increases
785 cortical synaptogenesis. Neurobiol Aging 29, 554-565.
786 Beyer, A.S., von Einem, B., Schwanzar, D., Keller, I.E., Hellrung, A., Thal, D.R., Ingelsson,
787 M., Makarova, A., Deng, M., Chhabra, E.S., Pröpper, C., Böckers, T.M., Hyman, B.T., von
788 Arnim, C.A., 2012. Engulfment adapter PTB domain containing 1 interacts with and affects
789 processing of the amyloid-β precursor protein. Neurobiol Aging 33, 732-743.
790 Burnham, K.P., Anderson, D.R., 2002. Model Selection and Multimodel Inference. Springer,
791 New York.

792 Chasseigneaux, S., Allinquant, B., 2012. Functions of Aβ, sAPPα and sAPPβ : similarities and
793 differences. J Neurochem 120 Suppl 1, 99-108.
794 Chasseigneaux, S., Dinc, L., Rose, C., Chabret, C., Coulpier, F., Topilko, P., Mauger, G.,
795 Allinquant, B., 2011. Secreted amyloid precursor protein β and secreted amyloid precursor
796 protein α induce axon outgrowth in vitro through Egr1 signaling pathway. PLoS One 6, e16301.
797 Claasen, A.M., Guévremont, D., Mason-Parker, S.E., Bourne, K., Tate, W.P., Abraham, W.C.,
798 Williams, J.M., 2009. Secreted amyloid precursor protein-alpha upregulates synaptic protein
799 synthesis by a protein kinase G-dependent mechanism. Neurosci Lett 460, 92-96.
800 Colciaghi, F., Marcello, E., Borroni, B., Zimmermann, M., Caltagirone, C., Cattabeni, F.,
801 Padovani, A., Di Luca, M., 2004. Platelet APP, ADAM 10 and BACE alterations in the early
802 stages of Alzheimer disease. Neurology 62, 498-501.
803 Copanaki, E., Chang, S., Vlachos, A., Tschäpe, J.A., Müller, U.C., Kögel, D., Deller, T., 2010.
804 sAPPalpha antagonizes dendritic degeneration and neuron death triggered by proteasomal
805 stress. Mol Cell Neurosci 44, 386-393.
806 Cuchillo-Ibañez, I., Lopez-Font, I., Boix-Amorós, A., Brinkmalm, G., Blennow, K.,
807 Molinuevo, J.L., Sáez-Valero, J., 2015. Heteromers of amyloid precursor protein in
808 cerebrospinal fluid. Mol Neurodegener 10, 2.
809 Dotti, C.G., Sullivan, C.A., Banker, G.A., 1988. The establishment of polarity by hippocampal
810 neurons in culture. J Neurosci 8, 1454-1468.
811 Dünkler, A., Rösler, R., Kestler, H.A., Moreno-Andrés, D., Johnsson, N., 2015. SPLIFF: A
812 Single-Cell Method to Map Protein-Protein Interactions in Time and Space. Methods Mol Biol
813 1346, 151-168.
814 El-Ansary, A., Al-Ayadhi, L., 2014. GABAergic/glutamatergic imbalance relative to excessive
815 neuroinflammation in autism spectrum disorders. J Neuroinflammation 11, 189.
816 Fol, R., Braudeau, J., Ludewig, S., Abel, T., Weyer, S.W., Roederer, J.P., Brod, F., Audrain,
817 M., Bemelmans, A.P., Buchholz, C.J., Korte, M., Cartier, N., Müller, U.C., 2015. Viral gene
818 transfer of APPsα rescues synaptic failure in an Alzheimer's disease mouse model. Acta
819 Neuropathol.
820 Friedrich, M.W., Aramuni, G., Mank, M., Mackinnon, J.A., Griesbeck, O., 2010. Imaging
821 CREB activation in living cells. J Biol Chem 285, 23285-23295.
822 Furukawa, K., Barger, S.W., Blalock, E.M., Mattson, M.P., 1996a. Activation of K+ channels
823 and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature 379,
824 74-78.
825 Furukawa, K., Mattson, M.P., 1998. Secreted amyloid precursor protein alpha selectively
826 suppresses N-methyl-D-aspartate currents in hippocampal neurons: involvement of cyclic
827 GMP. Neuroscience 83, 429-438.
828 Furukawa, K., Sopher, B.L., Rydel, R.E., Begley, J.G., Pham, D.G., Martin, G.M., Fox, M.,
829 Mattson, M.P., 1996b. Increased activity-regulating and neuroprotective efficacy of alpha-
830 secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding
831 domain. J Neurochem 67, 1882-1896.
832 Goetz, A.K., Scheffler, B., Chen, H.X., Wang, S., Suslov, O., Xiang, H., Brüstle, O., Roper,
833 S.N., Steindler, D.A., 2006. Temporally restricted substrate interactions direct fate and
834 specification of neural precursors derived from embryonic stem cells. Proc Natl Acad Sci U S
835 A 103, 11063-11068.
836 Goodman, Y., Mattson, M.P., 1994. Secreted forms of beta-amyloid precursor protein protect
837 hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Exp Neurol 128,
838 1-12.
839 Grabrucker, A., Vaida, B., Bockmann, J., Boeckers, T.M., 2009. Synaptogenesis of
840 hippocampal neurons in primary cell culture. Cell Tissue Res 338, 333-341.
841 Grabrucker, A.M., Knight, M.J., Proepper, C., Bockmann, J., Joubert, M., Rowan, M.,
842 Nienhaus, G.U., Garner, C.C., Bowie, J.U., Kreutz, M.R., Gundelfinger, E.D., Boeckers, T.M.,

843 2011. Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation.
844 EMBO J 30, 569-581.
845 Götz, J., Schonrock, N., Vissel, B., Ittner, L.M., 2009. Alzheimer's disease selective
846 vulnerability and modeling in transgenic mice. J Alzheimers Dis 18, 243-251.
847 Hasebe, N., Fujita, Y., Ueno, M., Yoshimura, K., Fujino, Y., Yamashita, T., 2013. Soluble β-
848 amyloid Precursor Protein Alpha binds to p75 neurotrophin receptor to promote neurite
849 outgrowth. PLoS One 8, e82321.
850 Hick, M., Herrmann, U., Weyer, S.W., Mallm, J.P., Tschäpe, J.A., Borgers, M., Mercken, M.,
851 Roth, F.C., Draguhn, A., Slomianka, L., Wolfer, D.P., Korte, M., Müller, U.C., 2015. Acute
852 function of secreted amyloid precursor protein fragment APPsα in synaptic plasticity. Acta
853 Neuropathol 129, 21-37.
854 Hires, S.A., Zhu, Y., Tsien, R.Y., 2008. Optical measurement of synaptic glutamate spillover
855 and reuptake by linker optimized glutamate-sensitive fluorescent reporters. Proc Natl Acad Sci
856 U S A 105, 4411-4416.
857 Hock, C., Golombowski, S., Müller-Spahn, F., Naser, W., Beyreuther, K., Mönning, U.,
858 Schenk, D., Vigo-Pelfrey, C., Bush, A.M., Moir, R., Tanzi, R.E., Growdon, J.H., Nitsch, R.M.,
859 1998. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in
860 Alzheimer's disease and major depression - inverse correlation with dementia severity. Eur
861 Neurol 39, 111-118.
862 Holsinger, R.M., McLean, C.A., Collins, S.J., Masters, C.L., Evin, G., 2004. Increased beta-
863 Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol 55, 898-
864 899.
865 Janssens, N., Lesage, A.S., 2001. Glutamate receptor subunit expression in primary neuronal
866 and secondary glial cultures. J Neurochem 77, 1457-1474.
867 Ji, Y., Lu, Y., Yang, F., Shen, W., Tang, T.T., Feng, L., Duan, S., Lu, B., 2010. Acute and
868 gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. Nat
869 Neurosci 13, 302-309.
870 Johnson-Venkatesh, E.M., Umemori, H., 2010. Secreted factors as synaptic organizers. Eur J
871 Neurosci 32, 181-190.
872 Kaech, S., Banker, G., 2006. Culturing hippocampal neurons. Nat Protoc 1, 2406-2415.
873 Kennedy, M.E., Stamford, A.W., Chen, X., Cox, K., Cumming, J.N., Dockendorf, M.F., Egan,
874 M., Ereshefsky, L., Hodgson, R.A., Hyde, L.A., Jhee, S., Kleijn, H.J., Kuvelkar, R., Li, W.,
875 Mattson, B.A., Mei, H., Palcza, J., Scott, J.D., Tanen, M., Troyer, M.D., Tseng, J.L., Stone,
876 J.A., Parker, E.M., Forman, M.S., 2016. The BACE1 inhibitor verubecestat (MK-8931) reduces
877 CNS β-amyloid in animal models and in Alzheimer's disease patients. Sci Transl Med 8,
878 363ra150.
879 Klarenbeek, J., Goedhart, J., van Batenburg, A., Groenewald, D., Jalink, K., 2015. Fourth-
880 generation epac-based FRET sensors for cAMP feature exceptional brightness, photostability
881 and dynamic range: characterization of dedicated sensors for FLIM, for ratiometry and with
882 high affinity. PLoS One 10, e0122513.
883 Lannfelt, L., Basun, H., Wahlund, L.O., Rowe, B.A., Wagner, S.L., 1995. Decreased alpha-
884 secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat
885 Med 1, 829-832.
886 Lazarov, O., Demars, M.P., 2012. All in the Family: How the APPs Regulate Neurogenesis.
887 Front Neurosci 6, 81.
888 Lazarov, O., Marr, R.A., 2010. Neurogenesis and Alzheimer's disease: at the crossroads. Exp
889 Neurol 223, 267-281.
890 Lomax, R.G., Hahs-Vaughn, D.L., 2012. Statistical Concepts: A

891 Second Course. Routledge Chapman & Hall, New York.
892 Luján, R., Shigemoto, R., López-Bendito, G., 2005. Glutamate and GABA receptor signalling
893 in the developing brain. Neuroscience 130, 567-580.

Mattson, M.P., Cheng, B., Culwell, A.R., Esch, F.S., Lieberburg, I., Rydel, R.E., 1993. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10, 243-254.

Motulsky, H.J., Ransnas, L.A., 1987. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J 1, 365-374.

Nicolas, M., Hassan, B.A., 2014. Amyloid precursor protein and neural development. Development 141, 2543-2548.

Nikolaev, A., McLaughlin, T., O'Leary, D.D., Tessier-Lavigne, M., 2009. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981-989.

Palmert, M.R., Usiak, M., Mayeux, R., Raskind, M., Tourtellotte, W.W., Younkin, S.G., 1990. Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. Neurology 40, 1028-1034.

Peters-Libeu, C., Campagna, J., Mitsumori, M., Poksay, K.S., Spilman, P., Sabogal, A., Bredesen, D.E., John, V., 2015. sAβPPα is a Potent Endogenous Inhibitor of BACE1. J Alzheimers Dis 47, 545-555.

Prox, J., Rittger, A., Saftig, P., 2012. Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and presenilin. Exp Brain Res 217, 331-341.

Ray, B., Long, J.M., Sokol, D.K., Lahiri, D.K., 2011. Increased secreted amyloid precursor protein-α (sAPPα) in severe autism: proposal of a specific, anabolic pathway and putative biomarker. PLoS One 6, e20405.

Ring, S., Weyer, S.W., Kilian, S.B., Waldron, E., Pietrzik, C.U., Filippov, M.A., Herms, J., Buchholz, C., Eckman, C.B., Korte, M., Wolfer, D.P., Müller, U.C., 2007. The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J Neurosci 27, 7817-7826.

Roch, J.M., Masliah, E., Roch-Levecq, A.C., Sundsmo, M.P., Otero, D.A., Veinbergs, I., Saitoh, T., 1994. Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor. Proc Natl Acad Sci U S A 91, 7450-7454.

Rohe, M., Carlo, A.S., Breyhan, H., Sporbert, A., Militz, D., Schmidt, V., Wozny, C., Harmeier, A., Erdmann, B., Bales, K.R., Wolf, S., Kempermann, G., Paul, S.M., Schmitz, D., Bayer, T.A., Willnow, T.E., Andersen, O.M., 2008. Sortilin-related receptor with A-type repeats (SORLA) affects the amyloid precursor protein-dependent stimulation of ERK signaling and adult neurogenesis. J Biol Chem 283, 14826-14834.

Ryan, M.M., Morris, G.P., Mockett, B.G., Bourne, K., Abraham, W.C., Tate, W.P., Williams, J.M., 2013. Time-dependent changes in gene expression induced by secreted amyloid precursor protein-alpha in the rat hippocampus. BMC Genomics 14, 376.

Selkoe, D.J., Hardy, J., 2016. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med.

SHOLL, D.A., 1953. Dendritic organization in the neurons of the visual and motor cortices of the cat. J Anat 87, 387-406.

Singh, B., Henneberger, C., Betances, D., Arevalo, M.A., Rodríguez-Tébar, A., Meier, J.C., Grantyn, R., 2006. Altered balance of glutamatergic/GABAergic synaptic input and associated changes in dendrite morphology after BDNF expression in BDNF-deficient hippocampal neurons. J Neurosci 26, 7189-7200.

Suh, J., Choi, S.H., Romano, D.M., Gannon, M.A., Lesinski, A.N., Kim, D.Y., Tanzi, R.E., 2013. ADAM10 missense mutations potentiate β-amyloid accumulation by impairing prodomain chaperone function. Neuron 80, 385-401.

Tai, H.C., Serrano-Pozo, A., Hashimoto, T., Frosch, M.P., Spires-Jones, T.L., Hyman, B.T., 2012. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease

is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 181, 1426-1435.
Takano, T., Xu, C., Funahashi, Y., Namba, T., Kaibuchi, K., 2015. Neuronal polarization. Development 142, 2088-2093.
Taylor, C.J., Ireland, D.R., Ballagh, I., Bourne, K., Marechal, N.M., Turner, P.R., Bilkey, D.K., Tate, W.P., Abraham, W.C., 2008. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol Dis 31, 250-260.
Wang, B., Wang, Z., Sun, L., Yang, L., Li, H., Cole, A.L., Rodriguez-Rivera, J., Lu, H.C., Zheng, H., 2014. The amyloid precursor protein controls adult hippocampal neurogenesis through GABAergic interneurons. J Neurosci 34, 13314-13325.
Wang, S.S., Held, R.G., Wong, M.Y., Liu, C., Karakhanyan, A., Kaeser, P.S., 2016. Fusion Competent Synaptic Vesicles Persist upon Active Zone Disruption and Loss of Vesicle Docking. Neuron 91, 777-791.
Young-Pearse, T.L., Chen, A.C., Chang, R., Marquez, C., Selkoe, D.J., 2008. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev 3, 15.
Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M.E., Buchhave, P., Londos, E., Umek, R.M., Minthon, L., Simon, A.J., Blennow, K., 2008. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65, 1102-1107.
Zhang, X., Odom, D.T., Koo, S.H., Conkright, M.D., Canettieri, G., Best, J., Chen, H., Jenner, R., Herbolsheimer, E., Jacobsen, E., Kadam, S., Ecker, J.R., Emerson, B., Hogenesch, J.B., Unterman, T., Young, R.A., Montminy, M., 2005. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A 102, 4459-4464.

Figure Legends

Figure 1: **Morphological analysis of primary hippocampal neurons upon His-EGFP-sAPP treatment at DIV4 and DIV7.** DIV2 PHNs were treated with 100nM His-EGFP-sAPPα or His-EGFP-sAPPβ and fixed and stained at DIV4 (A-C) or DIV7 (D-H). A) Boxplots comparing primary axon lengths of PHNs treated with control peptide and His-EGFP-sAPP treated neurons. Statistical analysis revealed that there is no statistically significant difference between

986 His-EGFP-control and His-EGFP-sAPP treated groups. $p < 0.05$, One-Way ANOVA, Kruskal-
987 Wallis Test. B) Boxplots comparing entire neurite lengths of PHNs treated with His-EGFP-
988 control peptide and His-EGFP-sAPP treated neurons. Statistical analysis revealed that there is
989 no statistically significant difference between control and His-EGFP-sAPP treated groups. $p <$
990 0.05, One-Way ANOVA, Kruskal-Wallis Test. C) Boxplots comparing neurite numbers of
991 PHNs treated with His-EGFP-control peptide and His-EGFP-sAPP treated neurons. Statistical
992 analysis revealed that there is no statistically significant difference between His-EGFP-control
993 and His-EGFP-sAPP treated groups. $p < 0.05$, One-Way ANOVA, Kruskal-Wallis Test. D)
994 Boxplots comparing primary axon lengths of PHNs treated with His-EGFP-control peptide and
995 His-EGFP-sAPP treated neurons. Statistical analysis revealed that there is a statistically
996 significant difference between His-EGFP-control and His-EGFP-sAPPα treated group. $p <$
997 0.05, One-Way ANOVA, Kruskal-Wallis test. E) Boxplots comparing entire neurite lengths of
998 PHNs treated with His-EGFP-control peptide and His-EGFP-sAPP treated neurons. Statistical
999 analysis revealed that there is a statistically significant difference between His-EGFP-control
1000 and His-EGFP-sAPPα as well as His-EGFP-sAPPβ treated groups. $p < 0.05$, One-Way
1001 ANOVA, Kruskal-Wallis Test. F) Boxplots comparing neurite numbers of PHNs treated with
1002 His-EGFP-control peptide and His-EGFP-sAPP treated neurons. Statistical analysis revealed
1003 that there is a statistically significant difference between His-EGFP-control and His-EGFP-
1004 sAPPα as well as His-EGFP-sAPPβ treated groups. $p < 0.05$, One-Way ANOVA, Kruskal-
1005 Wallis Test. G) Representative diagram view of sholl analysis of dendritic complexity from
1006 PHNs. H) Sholl analysis of dendritic complexity of PHNs treated with His-EGFP-control
1007 peptide or His-EGFP-sAPPα (upper plot) / His-EGFP-sAPPβ (lower plot). Each group
1008 comprises N=60 neurons from 3 independent cultures (~180 neurons in total for Fig. 1 A-F and
1009 ~60 neurons in total for Fig. 1 H). Asterisks indicate a statistically significant difference
1010 between His-EGFP-control and His-EGFP-sAPP treated groups. *$p < 0.05$, **$p < 0.01$, ***$p <$
1011 0.001, position wise Wilcoxon-test (26 tests, Bonferroni correction for multiple testing).
1012 Overall differences of curves are tested with the CuCompare software.

1013 Figure 2: **Advanced glutamatergic architecture upon mCherry-sAPP overexpression.**
1014 PHNs were lentiviral transduced at 2DIV with either mCherry-control, mCherry-sAPPα or
1015 mCherry-sAPPβ virus. A) Exemplary hippocampal neuron picture of mCherry-control,
1016 mCherry-sAPPα and mCherry-sAPPβ transduced neurons. Neurons were fixed at DIV14 and
1017 stained with Homer1 (red) and Bassoon (green) antibodies. Colocalizations indicating a mature
1018 glutamatergic synapse were counted and normalized to 10µm dendrite length. Scale bar: 10µm
1019 B) Statistical analysis revealed a significant higher number of Homer1/Bassoon colocalizations

1020 upon mCherry-sAPPα as well as mCherry-sAPPβ overexpression. $p < 0.0001$, Kruskal-Wallis
1021 test. 180 neurons from 3 independent cultures were analyzed for each condition. C) Analysis of
1022 Homer1/Bassoon colocalizations after mCherry-control, mCherry-sAPPα or mCherry-sAPPβ
1023 overexpression (plotted according to cumulative frequency) revealed that mCherry-sAPPα as
1024 well as mCherry-sAPPβ lead to a homogenous rightward shift in the frequency curve. D)
1025 Exemplary images of synaptic ultrastructure of mCherry-control, mCherry-sAPPα and
1026 mCherry-sAPPβ overexpressing hippocampal DIV14 neurons obtained by transmission
1027 electron microscopy. Asterisks indicate the postsynaptic density. Scale bar: 100 nm. E)
1028 Statistical analysis revealed a significant increase of postsynaptic density layer thickness of
1029 mCherry-sAPPα exposed neurons. $p < 0.0001$, Kruskal-Wallis test. 60 PSDs from three
1030 independent cultures were analyzed for each condition F) Analysis of layer thicknesses of PSDs
1031 after mCherry-control, mCherry-sAPPα or mCherry-sAPPβ overexpression (plotted according
1032 to cumulative frequency) revealed that mCherry-sAPPα lead to a rightward shift in the
1033 frequency curve.

1034 Figure 3: **Glutamate sensitivity of DIV7 PHNs is increased upon His-EGFP-sAPP**
1035 **treatment.** A) 15 minutes pre-Incubation of PHNs with both His-EGFP-sAPPα and His-EGFP-
1036 sAPPβ (1 nM) increase the Ca^{2+}-influx in DIV14 PHNs upon glutamate (10 µM) stimulation.
1037 n=3, N=18 wells; $p < 0.05$, Two-Way ANOVA, Dunnett's post hoc test. B-C) DIV2 PHNs
1038 were treated with 100nM His-EGFP-sAPPα or His-EGFP-sAPPβ and stimulated with 10 µM
1039 glutamate at DIV4, DIV7 or DIV14 respectively. To determine phospho ERK2 (lower bands)
1040 and phospho CREB1 levels Western blots were quantified by densitometric analysis. p-ERK2
1041 levels were normalized to t-ERK2 levels and p-CREB1 levels were normalized to total levels
1042 of CREB1 B) Relative protein levels of p-ERK2 were significantly increased upon His-EGFP-
1043 sAPPα treatment at DIV7. $p = 0.02$ Kruskal-Wallis Test. n=3 independent cultures. p-ERK2/t-
1044 ERK2 ratio was not significantly altered upon His-EGFP-sAPP treatment and glutamate
1045 stimulation at DIV4 and DIV14. C) Relative protein levels of p-CREB1 were significantly
1046 increased upon His-EGFP-sAPPα treatment and increased by trend after His-EGFP-sAPPβ
1047 treatment at DIV7. His-EGFP-sAPPα vs His-EGFP-control: $p = 0.001$, His-EGFP-sAPPβ vs.
1048 His-EGFP-control: $p = 0.056$. Kruskal-Wallis test. n=3 independent cultures, at least three
1049 technical replicates per culture. P-CREB1/t-CREB1 ratio was not significantly altered upon
1050 His-EGFP-sAPP treatment and glutamate stimulation at DIV4 and DIV14.

1051 Figure 4: **mCherry-sAPP overexpression lead to advanced glutamatergic architecture at**
1052 **DIV14 comparable to control treated DIV21 neurons but it suppresses the formation of**

1053 **GABAergic inputs.** PHNs were lentiviral transduced at DIV2 with either mCherry-control,
1054 mCherry-sAPPα or mCherry-sAPPβ virus. mCherry-sAPP treated neurons were fixed and
1055 stained at DIV14. mCherry-Control treated neurons were fixed and stained and DIV14 and
1056 DIV21. A) Exemplary PHN dendrites after overexpression of control construct and fixed at
1057 DIV14 and DIV21 and overexpression of mCherry-sAPPα or mCherry-sAPPβ fixed at DIV14.
1058 Presynapses were stained by VGlut1 antibodies. B) Statistical analysis revealed a significant
1059 higher number VGLUT1 positive puncta (presynaptic marker) upon mCherry-sAPPα as well
1060 as mCherry-sAPPβ overexpression. PHNs overexpressing the control construct $p < 0.0001$,
1061 Kruskal-Wallis test. 60 neurons from 3 independent cultures were analyzed for each condition.
1062 C) Exemplary PHN dendrites after overexpression of control construct and fixed at DIV14 and
1063 DIV21 and overexpression of mCherry-sAPPα or mCherry-sAPPβ fixed at DIV14. Presynapses
1064 were stained by VGAT antibodies. B) Statistical analysis revealed a significant higher number
1065 VGAT positive puncta (presynaptic marker) upon mCherry-sAPPα as well as mCherry-sAPPβ
1066 overexpression. PHNs overexpressing the control construct $p < 0.0001$, Kruskal-Wallis test. 60
1067 neurons from 3 independent cultures were analyzed for each condition. E) The E/I ratio was
1068 calculated by dividing the average number of VGlut1 pos. puncta by the average number of
1069 VGAT pos. puncta along 10 µm dendrite length. The foldchange over control was calculated
1070 and plotted. E/I ratio at DIV14 of mCherry-sAPPα as well as mCherry-sAPPβ treated neurons
1071 is significantly increased compared to mCherry-control treated neurons. When comparing
1072 DIV14 control treated neurons with DIV21 mCherry-control treated neurons, no significant
1073 change was observed. $p < 0.0001$, One-Way ANOVA, Kruskal-Wallis test, Dunn's post-hoc
1074 test. F) Schematic diagram for proposed functions of sAPPs in modulating glutamatergic
1075 development in PHNs.

1076 Figure 5: **sAPPα levels are significantly reduced in brain homogenates of AD patients.** A)
1077 Qualitative Western blot analysis of 14 human brains (seven control and seven AD brains)
1078 revealed that sAPPα is detectable by a specific sAPPα antibodies in human brain homogenates
1079 and that sAPPα levels are significantly lower in AD brain homogenates compared to control
1080 subjects. $p = 0.007$, Mann-Whitney *U*-test. B) Enrichment of synaptic fraction showed that
1081 sAPPα are detectable in the corresponding synaptic pellets and a trend of reduced sAPPα levels
1082 in AD synaptoneurosomes compared to control subjects was observed. $p = 0.128$, Mann-
1083 Whitney *U*-test. Western blots were quantified by densitometric analysis.

1084 Figure S1: **Qualitative analysis of recombinant His-EGFP-sAPPs produced in Flp-In-**
1085 **HEK293 cells and by using a lentiviral system reveals no cross contamination between**

1086 **sAPPα and sAPPβ production** A) Simply blue safe stained SDS-PAGE gel showing no side
1087 bands in His-EGFP-sAPPα and His-EGFP-sAPPβ elutions (His purification from HEK293 cell
1088 supernatant). B) Corresponding Western Blot to stained SDS-PAGE gel. The upper blot shows
1089 bands detected with an anti β-Amyloid antibody (6e10). In the His-EGFP-sAPPα elution lane
1090 a band at ~120 kDa can be detected, whereas no band is visible in the His-EGFP-sAPPβ elution
1091 lane. The lower blot shows bands detected with an antibody directed against the n-terminus of
1092 APP (22c11). There are bands at ~120 kDa visible in the His-EGFP-sAPPα and His-EGFP-
1093 sAPPβ elution lane. C) Western Blots showing the supernatant of DIV14 PHNs upon sAPP
1094 lentiviral transduction at DIV2. The left blot shows a band detected with an anti β-Amyloid
1095 antibody (6e10) in the supernatant of mCherry-sAPPα transduced neurons. The right blot shows
1096 bands detected with an antibody directed against the n-terminus of APP (22c11) in the
1097 supernatant of mCherry-sAPPα and mCherry-sAPPβ transduced neurons. No band is visible in
1098 the supernatant of mCherry-pUltra hot transduced neurons. D) Schematic illustration of
1099 specificity of the used antibodies for the qualification of recombinant sAPP production.

1100 Figure S2: **Exemplary images of DIV4 and DIV7 PHNs used for morphometric analysis**
1101 **upon control peptide and His-EGFP-sAPP treatment.** A-C) PHNs were treated with control
1102 peptide or His-EGFP-sAPPs at DIV2 and stained at DIV4 with an anti-beta-III-tubulin antibody
1103 to assess the morphology of His-EGFP-control (A), His-EGFP-sAPPα (B) and His-EGFP-
1104 sAPPβ (C) treatment. D-F) PHNs were treated with His-EGFP-control peptide or His-EGFP-
1105 sAPPs at DIV2 and stained at DIV7 with anti-tau (red) and anti-MAP2 antibodies (green) to
1106 assess the morphology of His-EGFP-control (D), His-EGFP-sAPPα (E) and His-EGFP-sAPPβ
1107 (F) treatment. Scale bars: 100µm.

1108 Figure S3: **His-EGFP-sAPPα increases CREB-1 phosphorylation in SH-SY5Y cells in a**
1109 **time-dependent manner.** A) Ratiometric analysis of Venus and mTurquoise fluorescence
1110 intensities shows a significant increase of CREB-1 phosphorylation in SH-SY5Y cells upon
1111 His-EGFP-sAPPα pre-treatment (1nM). CREB phosphorylation was determined by the CREB-
1112 phosphorylation biosensor ICAP. Cells were stimulated with 10µM glutamate and
1113 Venus/mTurquoise intensities ratios were recorded after 5, 12, 19, 24, 30, 35, 40, 45, 50, 55
1114 and 60 minutes. B) Ratiometric analysis of Venus and mTurquoise fluorescence intensities
1115 shows no alterations of CREB-1 phosphorylation in SH-SY5Y cells upon His-EGFP-sAPPβ
1116 pre-treatment (1nM). CREB phosphorylation was determined by the CREB-phosphorylation
1117 biosensor ICAP. Cells were stimulated with 10µM glutamate and Venus/mTurquoise intensities
1118 ratios were recorded after 5, 12, 19, 24, 30, 35, 40, 45, 50, 55 and 60 minutes. His-EGFP-control

1119 group (N=21), His-EGFP-sAPPα (N=11), His-EGFP-sAPPβ (N=21). Asterisks indicate a
1120 statistically significant difference between His-EGFP-control and His-EGFP-sAPP α treated
1121 groups. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, position wise Wilcoxon-test (12 tests, Bonferroni
1122 correction for multiple testing). Overall differences of curves are tested with the CuCompare
1123 software.

1124 Figure S4: **sAPPβ is not detectable in human brain homogenates.** Western blot showing
1125 sAPPβ cleavage fragments. Full length sAPPβ at 90-100 kDA molecular weight is not
1126 detectable.

1127

1128

1129 Table S1: **Patient demographic data**

Edinburgh brain bank number	BBN NUMBER	Gender	diagnosis	Age[y]
SD001/16	28406	M	control	79
SD017/16	28793	F	control	79
SD018/16	28794	F	control	79
SD024/15	26495	M	control	78
SD051/15	19597	M	control	79
SD032/13	16425	M	control	61
SD063/13	19686	F	control	77
SD049/14	24322	M	AD	80
SD055/14	24526	M	AD	79
SD056/14	24527	M	AD	81
SD007/15	25056	M	AD	72
SD014/15	25739	F	AD	85
SD040/15	26718	M	AD	78
SD005/16	28410	F	AD	62

1130 M = male, F = female

1131

1132

1133 **Supplementary Methods:**

1134 **Measurement of the time-dependent phosphorylation of CREB1**

1135 To measure the time-dependent phosphorylation of CREB1 SH-SY5Y cells were transfected
1136 with a FRET based indicators of phosphorylation for CREB1 (pNLS- mTurquoise2Δ-11AA-
1137 ICAP- td_cp173Venus(d)_188_NES-pUltraHot) (Friedrich et al., 2010; Klarenbeek et al.,
1138 2015). On the day before the transfection SH-SY5Y cells were seeded onto a 96 Well Black
1139 Clear Flat Bottom TC-Treated Microplate (Corning, New York, USA) at a density of $4x10^4$

1140 cells per well. The cells were incubated overnight at 37 ° C and 5% CO2 in 10 ml DMEM plus
1141 10 % fetal calf serum and 1 % Penicillin with Streptomycin and are transfected the next morning
1142 according to the manufacturer's instructions of the LTX & Plus Reagent Kit. After another 24
1143 hours of incubation under the same conditions the cells were used for measurements in the
1144 microplate reader. To carry out the experiments the medium must be replaced by a clear wash
1145 buffer (for buffer composition see FLIPR-analysis part in Material & Methods section) which
1146 does not influence the fluorescence intensity to be measured. The 96 well plate was then placed
1147 in the to 37 ° C preheated Clariostar microplate reader (BMG Labtech, Ortenberg, Germany).
1148 In the reader, the cells were excited with a wavelength of 430 nm and the emission is measured
1149 at 480 nm and 550 nm. The first emission wavelength corresponds to the range in which
1150 mTurquoise2Δ emits, the second wavelength is slightly above the emission of the Venus
1151 fluorophore (530 nm) to avoid a blend with the emitting light of turquoise. Other important
1152 measurement settings are: focal height 3.8 mm, bottom reading and well scan with a 5x5 matrix.
1153 First the fluorescence intensities of the untreated cells were measured. Subsequently, the cells
1154 were treated with glutamate (final concentration 10 μM) and the fluorescence intensity was
1155 measured again at 5, 12, 19, 24, 30, 35, 40, 45, 50, 55 and 60 minutes after stimulation for the
1156 measurements of CREB-activity. For the measurements, the cells were pretreated with His-
1157 EGFP-sAPPα/β / His-EGFP-control peptide (1nM) for 24 h. The analysis of the measured
1158 fluorescence intensities was performed with the Clariostar Data Analysis software (BMG
1159 Labtech, Ortenberg, Germany). For the evaluation, the fluorescence intensity of Venus
1160 (detection at 550 nm) was set in relation to the fluorescence intensity of Turquoise (detection
1161 at 480 nm), the ratio was then standardised to the fluorescence ratio of the untreated and
1162 unstimulated cells.